Gliriv-M 2 Forte Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, formulated as a sustained-release tablet for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity without causing significant hypoglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Gliriv-M 2 Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Contraindications include severe renal or hepatic impairment, metabolic acidosis, and hypersensitivity to any component. Caution is advised in patients with cardiovascular disease and during periods of acute illness or surgery. This combination therapy offers a synergistic mechanism to improve glycemic control, reduce HbA1c levels, and minimize the risk of diabetes-related complications when used as part of a comprehensive diabetes management plan.